Sanofi completes $11.6bn acquisition of Bioverativ

In brief: Sanofi completes €3.9bn Ablynx acquisition
Credit: Patrick Wack / Capa Pictures

Sanofi has this week completed its acquisition of haemophilia-focused biopharmaceutical company Bioverativ.

The deal, which was originally announced in January and is worth a total $11.6 billion, sees Sanofi snap-up all the outstanding shares of Bioverativ.

“The addition of Bioverativ provides us with a strong position in the large and growing haemophilia market and expands our presence in specialty care,” said Sanofi CEP Olivier Brandicourt.

“Through a series of three strategic transactions—the addition of Bioverativ, our planned acquisition of Ablynx and our agreement for fitusiran—we are well on our way to creating a leading franchise in the field of rare blood disorders.”